FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:2534 June 16, 2005 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

View larger version (82K): [in this window] [in a new window]   A 62-year-old woman had progression of multiple myeloma despite many therapies, including an autologous hematopoietic stem-cell transplantation. Infusions of bortezomib (1.3 mg per square meter of body-surface area) were administered as an intravenous bolus twice weekly for 2 weeks, followed by a 10-day rest period. During the second treatment cycle, a purpuric rash, which was not associated with fever or itching, developed on the patient's trunk, back, hands, and face. A biopsy specimen of the skin lesion revealed a leukocytoclastic vasculitis. The patient was treated with 20 mg of prednisone, and the rash resolved. The rash recurred with subsequent cycles . . . [Full Text of this Article]

 

This article has been cited by other articles:

• Yang, C. H., Gonzalez-Angulo, A. M., Reuben, J. M., Booser, D. J., Pusztai, L., Krishnamurthy, S., Esseltine, D., Stec, J., Broglio, K. R., Islam, R., Hortobagyi, G. N., Cristofanilli, M. (2006). Bortezomib (VELCADE(R)) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol 17: 813-817 [Abstract] [Full Text]  
• Fernandez, Y., Miller, T. P., Denoyelle, C., Esteban, J. A., Tang, W.-H., Bengston, A. L., Soengas, M. S. (2006). Chemical Blockage of the Proteasome Inhibitory Function of Bortezomib: IMPACT ON TUMOR CELL DEATH. J. Biol. Chem. 281: 1107-1118 [Abstract] [Full Text]